jerry submitted, created time 6 months 2 weeks (care.diabetesjournals.org)

This is an analysis from a diabetes outcome progression trial.
It said that further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings

Submit comment | Blog It | Email It | Keywords: fractures diabetes bones pathophysiology Rosiglitazone Type 2 diabetes